SB 33: RIGHT TO TRY INDIVIDUALIZED TREATMENTS ACT
SB 33 status: Introduced — action postponed indefinitely (updated Mar 24, 2026).
What this bill does
Overall score
Bill summary
OfficialThis proposed law would allow patients with life-threatening illnesses to try custom-made, experimental treatments—like personalized gene therapies—even if they haven't been fully approved by the government yet. It is currently being reviewed in the Senate.
Key analysis
Impact analysis
Environment
Benefits
- No material effect on environmental policy.
Risks
- No material effect on environmental policy.
Economy
Benefits
- May stimulate niche demand for specialized clinical services.
Risks
- Potential for unforeseen legal or insurance-related litigation costs.
Society
Benefits
- Increases patient autonomy for life-threatening conditions.
- Expands access to potential life-saving personalized medicine.
Risks
- Risk of exposure to unproven or dangerous medical interventions.
- Lack of standardized clinical oversight for custom treatments.
How trustworthy & consequential it is
Source
OpenStates
Confidence
lowlow
Analysis status
OpenStates summary
Potential for safety risks due to bypassed FDA-style clinical trial rigor.
Analysis based on summary abstract only.
Where it stands
Introduced
Currentaction postponed indefinitely
Committee
UpcomingFloor
UpcomingGovernor
UpcomingEnacted
UpcomingHow it affects your district
Set your location
Add your district to see how this bill may affect your community and who to contact.
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.